HONG KONG – With operations in the U.S, the Netherlands and China, Shanghai-based biopharma firm Harbour Biomed Therapeutics Ltd. inked a 10-year pact with Erasmus MC from the University Medical Center Rotterdam to grow its footprint in Europe. Both sides will develop biotherapeutics to treat cancer and immunological diseases.